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Nursing home placement in the donepezil and memantine in moderate to severe Alzheimer's 
disease (DOMINO) trial: secondary and post-hoc analyses of a randomised trial 
 
Structured abstract 
 
Background: Observational studies have suggested delay in nursing home placement (NHP) with 
dementia drug treatment, but an earlier randomised trial in patients with mild to moderate 
Alzheimer’s disease (AD) showed no effect. We investigated the effects of continuing or discontinuing 
donepezil and starting memantine on subsequent NHP in moderate to severe AD.  
Methods: In the DOMINO trial (ISRCTN49545034) 295 community living patients with moderate to 
severe AD recruited from 15 centres in England and Scotland from February 2008 to March 2010 were 
randomised with double-blind placebo-control to continue donepezil (73), discontinue donepezil (73), 
discontinue donepezil and start memantine (76), or continue donepezil and start memantine (73) for 
52 weeks. After 52 weeks choice of treatment was left to participants and their physicians. Place of 
residence was recorded at outcomes assessment points during the first 52 weeks of the trial and 
subsequently every 26 weeks for a further 3 years. Nursing home placement was an irreversible move 
from independent accommodation to a residential caring facility and was a secondary trial endpoint. 
Analyses restricted to the risk of placement in the first year of follow-up were post-hoc. 
Findings: 162 patients (55%) underwent NHP within 4 years of randomisation. Numbers of NHPs were 
similar for all arms (36 in patients who continued donepezil, 42 who discontinued donepezil, 41 who 
discontinued donepezil and started memantine, and 43 who continued donepezil and started 
memantine). There was significant (p=0.010) heterogeneity of treatment effect over time with 
significantly more NHPs in the donepezil discontinuation group during the first year (HR 2.09 (95% CI, 
1.29 to 3.39)) and no difference later (HR 0.89 (95% CI, 0.58 to 1.35)). Subsequent analyses focussed 
on the first year of the trial and on donepezil only were post-hoc. 1-year NHP risk was 17% higher (95% 
CI 6% to 28%) in patients allocated to discontinue donepezil compared to continuing donepezil. There 
was no effect of starting memantine compared to no memantine during the first year (HR 0.92 (95% 
CI 0.58 to 1.45)) or later (HR 1.23 (95% CI 0.81 to 1.87)); difference in 1-year NHP risk 1% (95% CI -12% 
to 10%). 
 
Interpretation: Withdrawing donepezil in patients with moderate to severe AD increased the risk of 
NHP during 12 months of trial treatment, but made no difference to NHP over 4 years of follow-up. 
Decisions to stop or continue drug treatment at this stage should be informed by potential risks of 
withdrawal, even if the perceived benefits of continued treatment are not clear.    
Funding: Funded by the U.K. Medical Research Council and the Alzheimer’s Society. 
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Introduction 
Reasons for nursing home placement (NHP) in Alzheimer’s disease (AD) are complex, involving patient 
and caregiver characteristics as well as the cultural and social environment. White ethnicity, 
impairments in cognition and activities of daily living, behavioural problems and increased caregiver 
age and burden all predict nursing home placement in AD.1 Economic costs in dementia increase 
markedly with disease severity with NHP contributing substantially to total support costs in severe 
dementia. Whether cholinesterase inhibitors and memantine can delay the point at which AD patients 
make the transition to permanent residential care is controversial. AD2000, the only randomised 
controlled double-blind trial to directly address this question for donepezil was negative.2 
Observational studies, following patients who have participated in double-blind or open trials or 
received open label treatment with tacrine,3 donepezil,4 tacrine, donepezil or rivastigmine,5,6 
galantamine,7 or memantine combined with a cholinesterase inhibitor8 have reported positive results. 
These studies have been criticised as they have not involved randomisation, placebo-control or 
blinding of treatment allocation.9-12 The socioeconomic implications of resolving this controversy are 
clear. Models based on assumptions that the drugs can delay placement indicate large societal and 
healthcare cost savings.13  
We have previously shown that continued treatment with donepezil in patients with moderate to 
severe AD is associated with cognitive and functional benefits over the course of 12 months compared 
to tapering and discontinuing.14 It could be argued that modest cognitive and functional treatment 
benefits in moderate to severe dementia have only limited impact on the lives of patients and 
caregivers. An important secondary objective of our trial was to investigate whether continuing a drug 
treatment that improved dementia symptoms would also delay NHP in an AD population who had 
already reached the severity point at which independent home living was likely to be compromised. 
Trial participants have completed 4 years of double-blind follow-up and we now report how treatment 
allocation affected subsequent permanent NHP.  
    
Methods 
Study design and participants 
The Donepezil and Memantine in Moderate to Severe Alzheimer’s Disease (DOMINO) study 
(ISRCTN49545034) was a multicentre (15 secondary care Memory Services in England and Scotland), 
double-blind, placebo-controlled, clinical trial with a two-by-two factorial design.15 Eligible 
participants met standardized criteria16 for probable or possible moderate or severe AD, had been 
prescribed donepezil continuously for at least 3 months with a dose of 10 mg for at least the previous 
6 weeks, and had a score between 5 and 13 on the Standardised Mini-Mental State Examination.17  
Randomisation and masking 
The first 80 participants were assigned with the use of a prepared unrestricted randomised list of 
assignments to ensure allocation concealment.18 Thereafter, participants were randomly assigned to 
one of four treatment groups for 12 months: continuation of donepezil 10 mg per day, with placebo 
memantine; discontinuation of donepezil (following 4 weeks of treatment with 5 mg), with placebo 
memantine; discontinuation of donepezil and initiation of treatment with memantine 20 mg per day; 
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or continuation of donepezil 10 mg per day and initiation of memantine 20 mg per day. Treatment 
assignments were made by the U.K. Medical Research Council Clinical Trials Unit with the use of 
randomized minimization.18 Groups were stratified according to centre (among the 15 participating 
centres), duration of donepezil treatment before entry (3 to 6 months vs. >6 months), baseline SMMSE 
score (5 to 9 vs. 10 to 13), and age (<60 years, 60 to 74 years, or >74 years). Patients, caregivers, 
clinicians, outcome assessors, and investigators were blinded to treatment assignments.  
Outcome measures and trial procedures 
The primary outcomes of the trial were scores on the SMMSE and on the caregiver-rated Bristol 
Activities of Daily Living Scale. Results on these outcomes, along with neuropsychiatric symptoms, 
participant quality of life and caregiver psychological distress outcomes during completion of the 52 
week intervention have been reported in an earlier paper.14 In addition, the Client Service Receipt 
Inventory (CSRI)19 was completed for the 52 weeks of trial treatment. In the CSRI, the following are 
classified as NHP: care home providing nursing care, care home providing personal care, dual 
registered home (providing both personal and nursing care), acute psychiatric ward, general medical 
ward, rehabilitation ward) and the following as non-NHP: owner occupied house/flat, privately rented 
house/flat, house/flat rented from housing association or local authority, sheltered/warden 
controlled housing, extra care housing. The CSRI captured the patient’s “usual place of residence” 
since the last assessment, together with the number of days spent living in other locations. When the 
“usual place of residence” had changed to a NHP from the previous visit, the date of NHP was 
estimated as the number of days lived outside NHP since the previous assessment date subtracted 
from the assessment date at which the change was reported. Over the following 3 years, the caregiver 
was contacted by telephone every 26 weeks and asked whether the participant was still living at home 
or had moved to live permanently in a residential or nursing home, and if such a move had occurred, 
the date of transition. The definition of NHP and the date of transition to NHP remained the same 
throughout the study, despite the change in the method of data collection. The original planned 
sample size was 800, but was adjusted to 430 due to reduced standard deviations for the primary 
outcomes from an interim blinded analysis of trial data. The trial was designed with at least 90% power 
for the primary outcomes, but was not powered to show differences on time to NHP. Trial recruitment 
was conducted between 11 February 2008 and 5 March 2010 and the last participant completed 
follow-up in March 2014. 
 
Study oversight 
The study was overseen by King’s College London and was funded by the U.K. Medical Research 
Council and the Alzheimer’s Society. Full ethical approval was received from the Scotland A 
Multicentre Research Ethics Committee. Agreement in writing to take part in the study was obtained 
from participants if they had capacity to give informed consent, and the main caregivers gave written 
consent for their own involvement and assent for the patients’ participation. The corresponding 
author (RH) vouches for the accuracy and completeness of the data and for the fidelity of the study to 
the protocol. All authors had full access to all of the data in the study and can take responsibility for 
the integrity of the data and the accuracy of the data analysis. Data sharing: patient level data (without 
date of birth or recruiting centre) and the full dataset are available with open access from the 
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corresponding author. Consent was not obtained from participants for data sharing but the presented 
data are anonymised and risk of identification is low. 
Role of the funding source 
The UK Medical Research Council and Alzheimer’s Society who funded the trial had no role in the study 
design, the collection, analysis or interpretation of data, the writing of the report or the decision to 
submit for publication. Pfizer-Eisai and Lundbeck donated drug and placebo supplies but had no 
involvement in the design or conduct of the study or the analysis or reporting of the data. All authors 
had full access to all of the study data and Professor Howard had final responsibility for submitting the 
paper for publication. 
Statistical analysis 
Following the pre-specified statistical analysis plan, time to NHP was analysed using stratified log-rank 
(using randomisation minimisation factors as strata) and Cox proportional hazards regression with 
patients who died or who withdrew from follow-up before NHP censored at date of death or 
withdrawal. The assumption of proportion hazards was tested using the Shoenfeld residuals with 
ranking of follow-up time. Since this was a secondary endpoint for the trial, the statistical analysis plan 
did not include any pre-specified analyses in the event of non-proportional hazards, when the log-rank 
test has reduced power to detect differences and standard Cox regression is inappropriate. 
Subsequent analyses were not pre-specified in the analysis plan since the presence of non-
proportional hazards was not anticipated. For situations with evidence of non-proportional hazards (p 
< 0.05), follow-up was split into distinct periods with hazards assumed to be proportional within each 
period (piecewise proportional hazards modelling). Regression models with different time period 
splits were compared using the Akaike Information Criterion (AIC). Probability of NHP by time after 
randomisation was calculated from the Kaplan-Meier survivor function with 95% confidence intervals. 
Differences in centiles of survival time and probability of NHP between groups were calculated with 
95% bias-corrected bootstrap confidence intervals using 1000 bootstrap replications. The log-rank 
statistic was calculated for each strata and tabulated with event rate ratios using methods previously 
described20 to explore the effect of stratification. 
The protocol and statistical analysis plan pre-specified that death before NHP would be considered as 
a censoring event in the same way as withdrawal or loss from follow-up. However, NHP may have 
been more likely in patients who died compared to those who withdrew from follow-up had the 
patients not died or withdrawn respectively. We therefore conducted two additional sensitivity 
analyses: 1) considering all deaths as NHP events at the time of death (equivalent to the composite 
endpoint of death or NHP) and 2) a competing risks analysis21 modelling the sub-hazard function of 
NHP in the presence of the competing risk of death.  
The following patient baseline covariates were evaluated for association with time to NHP in the 
regression model: age, gender, prior duration of donepezil treatment, centre, ethnicity, gender of 
carer, relationship of carer, whether patient lives with carer, sMMSE, BADLS, NPI, DEMQOL-proxy, EQ-
5D health state, and NPI subscales of  delusions, hallucinations, agitation/aggression and 
irritability/lability. Covariates were only considered as predictors if the treatment-adjusted effect was 
significant at the 5% level in separate univariable models. 
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In addition, parametric models were used to describe how the underlying risk of NHP changes with 
time. The following standard parametric models were fitted to the data: Weibull, generalized gamma, 
log-normal, log-logistic and Gompertz. Flexible parametric survival models do not assume an 
underlying log-linear relationship with time or with hazard and allow a more flexible fully parametric 
modelling approach.22 These were compared with standard parametric models, with the best fitting 
model chosen using the AIC. 
 
Results 
Of the 295 patients randomised into the trial, 162 (55%) had NHP within 4 years of randomisation. 
Table 1 summarises the patient baseline characteristics and Table 2 time to NHP in each of the four 
treatment groups.  Figure 1 shows the patient flowchart. 
Primary analysis (pre-specified) 
There was evidence of a difference in time to NHP between discontinuing and continuing donepezil 
(stratified log rank test, p=0.022), although non-significant in the un-stratified analysis (p=0.100). 
There was no evidence for an interaction (p=0.168 stratified, p=0.446 un-stratified) and no benefit of 
starting memantine (p=0.719 stratified, p=0.628 un-stratified). Subsequent analyses therefore only 
consider the effect of discontinuing donepezil. Figure 2A shows the Kaplan-Meier survival curve of 
cumulative probability of NHP by treatment arm. 
The 25th percentile of time to NHP was greater in patients continuing donepezil, 12.7 months (95% CI, 
10.4 to 14.0), as compared to 8.9 (95% CI, 5.5 to 10.1) months for patients discontinuing donepezil, a 
difference of 3.8 months (95% CI, 1.5 to 7.0). There was no difference in median time to NHP: 21.9 
months (95% CI, 16.9 to 29.1) and 16.7 months (95% CI, 12.7 to 22.1) respectively.  
Figure 3 shows the log rank statistics and event rate ratio for each strata and also by time period of 
NHP from randomisation, by whether patients were allocated to continue or discontinue donepezil.  
There was clear evidence of non-proportional hazards (p=0.01, Figure 2B) indicating that the overall 
hazard ratio of discontinuing compared to continuing donepezil was not an appropriate summary 
measure as the effect of discontinuing donepezil changed with time. Kaplan Meier survival curves 
appeared to separate over the first 12 months and were parallel thereafter. Subsequent results are 
based on analyses that were not pre-specified in the analysis plan since non-proportional hazards was 
not anticipated.  
Piecewise modelling in the presence of non-proportional hazards 
Splitting follow-up time at only 12 months resulted in better model fit, and lower AIC, than splits at 
any combination of 6, 12 and 24 months (data not shown). Discontinuing donepezil more than doubled 
the (instantaneous) probability of NHP over the first year (hazard ratio 2.09 (95% CI, 1.29 to 3.39)) 
compared to continuing donepezil (Table 3). This benefit was maintained after 12 months with curves 
remaining approximately equidistant (hazard ratio 0.89, (95% CI, 0.58 to 1.35)). This hazard ratio after 
12 months should be interpreted with caution due to selection bias;23 this is estimated from the sub-
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group of patients without NHP by 12 months which included more patients that had discontinued than 
had continued donepezil. 
Discontinuing donepezil treatment increased the probability of NHP over the first 6 months from 0.06 
to 0.19 (difference 0.13, 95% CI, 0.04 to 0.21) and over the first 12 months from 0.20 to 0.37 
(difference 0.17, 95% CI, 0.06 to 0.28), see Table 3. This indicates a number needed to treat of 5.88 
patients for 12 months to prevent 1 NHP. 
Patients who lived with their carers at baseline had a lower instantaneous risk of NHP throughout 
follow-up as compared to those that didn’t live with their carers (p=0.013, hazard ratio 0.63, 95% CI, 
0.44 to 0.89). This effect did not differ by treatment arm (p=0.48, test for interaction) and no other 
baseline covariates tested were associated with NHP (data not shown). 
Sensitivity analyses 
66 patients died before NHP with a further 26 deaths reported after NHP. There was no evidence for 
differences in time to death between arms (p=0.816 stratified, p=0.971 un-stratified). In both the 
analysis of the composite endpoint of death or NHP and the competing risks analysis, the results were 
consistent with no evidence of an effect of memantine and evidence of a large benefit with donepezil 
over the first 12 months that was maintained after 12 months (data not shown).  
Parametric survival models 
None of the standard parametric models provided a good fit for the data, unlike the flexible parametric 
survival model. The preferred model was a PH(1) model with 3 degrees of freedom for the time varying 
covariate of donepezil (active vs placebo). Figure 4 shows the fitted hazard function (Figure 4A) and 
survivor function (Figure 4B) from this model showing how the underlying risk of NHP changes with 
time. The risk of NHP in patients discontinuing donepezil is high in the first months, with a peak around 
6 months and steadily declining thereafter. The risk of NHP in patients continuing donepezil is lower 
over the first 12 months, with the peak not occurring until after 12 months and steadily declining after 
this. There is clear separation of the curves over the first 6-12 months with the risk of NHP 
approximately equal for both groups from 12 months onwards. 
 
 
Discussion 
This is the first randomised double-blind study to demonstrate a significant effect of dementia drug 
treatment on NHP. We found that discontinuing donepezil treatment in patients with moderate to 
severe AD was associated with a doubling of the instantaneous risk of placement to nursing homes 
over 12 months. There was no significant difference in the risk of placement at later follow-up points 
and there was no effect of starting memantine treatment, either singly or when combined with 
donepezil, at any point in the trial. We acknowledge that the comparison of time to NHP was a 
secondary objective of the DOMINO trial and that the analysis restricted to the first 12 months was 
not pre-specified in the statistical analysis plan. These results should therefore be considered 
exploratory and ideally would need to be confirmed in future studies. It is recommended that 
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restricted mean survival time may be a more appropriate treatment effect measure than (average) 
hazard ratio in the presence of non-proportional hazards. However, given the apparent disadvantages 
of withdrawing cholinesterase inhibitor treatment,14 data from further double-blind trials are unlikely 
to become available.  
The cholinesterase inhibitors are symptomatic treatments for AD and are not disease-modifying. How 
might symptom worsening, associated with withdrawal of donepezil, increase risk of nursing home 
placement? Yaffe and colleagues showed that impairment in activities of daily living (ADLs) was a more 
important predictor of NHP than cognitive impairment.1 In their study, Kaplan-Meier rates for NHP 
over 1 year were 24% for patients with a Mini-Mental State Examination (MMSE)24 score of 15 to 20, 
and 26% for MMSE score of <15, but 15% for those who were ADL independent and 25% for patients 
with one or more ADL dependency.1 Analysis of data from a long-term clinical trial showed that, 
although baseline ADL score influenced risk for and time to NHP, it was decline in ADL that most 
strongly predicted placement.25 Withdrawal from donepezil treatment in the DOMINO trial was 
associated with an average 3 point Bristol Activities of Daily Living Scale (BADLS)26 disadvantage during 
the 12 month intervention period.14 Given the established impact of ADL status and loss of ADLs upon 
the risk of NHP,1,25 it is most likely that the ADL worsening seen when patients were withdrawn from 
donepezil in the trial represents the mechanism for earlier NHP. 
Since NHP is influenced by social and living circumstances, preferences and values,1 and that an earlier 
RCT conducted by some of the authors of the current study reached unambiguously negative 
conclusions,2 is it truly plausible that donepezil treatment could significantly affect NHP? There are 
three important differences between the AD20002 and DOMINO14 trials that might have relevance in 
consideration of this point. First, DOMINO examined the effects of withdrawing established donepezil 
treatment27 while AD2000 investigated the effects of commencing treatment. Second, the mean 
MMSE score of patients entering AD2000 was 19 points, and for DOMINO 9 points. The participant 
populations were therefore very different in terms of dementia severity and proximity to the time of 
greatest risk of NHP. Only 9% of donepezil and 14% of placebo treated AD2000 patients moved to NHP 
in the first 12 months and it is possible that NHP was too rare an event in AD2000 for a treatment 
effect to be seen. Third, the magnitude of treatment effects on cognition and ADLs were greater in 
DOMINO than AD2000. Over 2 years, AD2000 participants who received donepezil were on average 
0.8 MMSE points and 1.0 BADLS points better than those on placebo,2 while the average 12-month 
drug-placebo differences for donepezil in DOMINO were 1.9 SMMSE points and 3.0 BADLS points.14 
Although they showed no overall effect on NHP, the AD2000 authors did find that BADLS and 
Neuropsychiatric Inventory28 scores, and age were strong independent predictors of NHP, and using a 
multivariate model, predicted that a 2 to 3 point improvement in BADLS with donepezil would have 
reduced the rate of institutionalisation in their sample by 10% in the first year. 
A limitation of our data is that we did not collect information about dementia drug use after the 52 
weeks of double-blind trial treatment was completed. Participants were not routinely unblinded 
following completion of the trial drug treatment and decisions about their subsequent treatment were 
made by their responsible clinician. A second limitation relates to our examination of follow-up 
periods. In the pre-specified primary analysis, as described in the Protocol, considering the whole 
follow-up period (using a stratified log rank test), there was a statistically significant effect for 
continuing donepezil as compared to withdrawing and substituting placebo (p =0.022). The piecewise 
modelling, however, considering time to NHP in the first 12 months that we carried out thereafter was 
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not a pre-specified analysis and this should be borne in mind in interpretation of the results. Further, 
withdrawal from study drug was significantly more common among participants assigned to 
discontinue donepezil than those assigned to continue14 and this should be borne in mind in 
consideration of the results. A strength of our data was that DOMINO was designed as a pragmatic 
study, to answer questions about the treatment of typical AD patients within 15 different public health 
services for people with dementia across England and Scotland, and the inclusion and exclusion 
criteria were relatively unselective, both to facilitate participant recruitment and to ensure study 
generalisability. 
The economic benefits of preventing or delaying NHP in AD are large and clear,13,29 as in the UK this 
reduces costs to the public purse, even if it increases the imputed costs of unpaid care, but there 
would also be important positive effects upon patient quality of life. A survey of caregivers indicated 
that they regarded NHP as a major negative determinant of quality of life, with more than two-thirds 
rating delaying NHP as “extremely important” or “very important” in maintaining quality of life.30 The 
decrease in the quality of life for people with dementia associated with NHP, along with societal costs 
of such placements have driven national policy in England to maintain people with dementia within 
their own households for as long as is possible. Our data suggest that withdrawing cholinesterase 
inhibitor treatment in moderate to severe AD brings forward the timing of NHP during the following 
52 weeks, but that this effect did not operate at later points during 4-year follow-up. This would be 
consistent with the effects of modest symptomatic improvement in cognition and function associated 
with these drugs.     
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Figure 1. Patient flowchart.
 
  
318 patients assessed for 
eligibility
295 randomised
73 assigned to have 
donepezil continued and 
active memantine added 
(Group 4)
Year 1 (73 at risk)
13(18%) NHP
7(10%) died
8(11%) withdrawn 
Year 2 (45 at risk)
17(38%) NHP
5(11%) died
0 withdrawn 
Year 3 (23 at risk)
6(26%) NHP
3(13%) died
1(4%) withdrawn 
Year 4 (13 at risk)
7(54%) NHP
2(15%) died
0 withdrawn 
4(31%) no NHP at end of 
follow-up
73 assigned to have 
donepezil continued and 
placebo memantine 
added (Group 3)
Year 1 (73 at risk)
13(18%) NHP
13(18%) died
5(7%) withdrawn 
Year 2 (42 at risk)
16(38%) NHP
2(5%) died
1(2%) withdrawn 
Year 3 (23 at risk)
4(17%) NHP
3(13%) died
0 withdrawn 
Year 4 (16 at risk)
3(19%) NHP
2(13%) died
0 withdrawn 
11(69%) no NHP at end 
of follow-up 
76 assigned to have 
donepezil discontinued 
and active memantine 
added (Group 2)
Year 1 (76 at risk)
22(29%) NHP
7(9%) died
15(20%) withdrawn 
Year 2 (32 at risk)
14(44%) NHP
4(13%) died
0 withdrawn 
Year 3 (14 at risk)
1(7%) NHP
0 died
0 withdrawn 
Year 4 (13 at risk)
4(31%) NHP
1(8%) died
0 withdrawn 
8(62%) no NHP at end of 
follow-up 
73 assigned to have 
donepezil discontinued 
and placebo memantine 
added (Group 1)
Year 1 (73 at risk)
24(33%) NHP
9(12%) died
6(8%) withdrawn 
Year 2 (34 at risk)
12(35%) NHP
4(12%) died
1(3%) withdrawn 
Year 3 (17 at risk)
4(24%) NHP
2(12%) died
0 withdrawn 
Year 4 (11 at risk)
2(18%) NHP
2(18%) died
0 withdrawn 
7(64%) no NHP at end of 
follow-up
23 were excluded
* 2 declined to participate
* 21 did not meet inclusion criteria
** 19 inadmissible sMMSE
** 1 no diagnosis of AD
** 1 not maintained on 10mg donepezil for 6 
weeks
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Figure 2:  Kaplan-Meier curve of cumulative probability of NHP (A) by treatment group, (B) by 
discontinue vs continue donepezil and (C) by adding memantine. Patients were allocated to 
discontinue donepezil (group 1), discontinue donepezil and start memantine, continue donepezil 
(group 3), or continue donepezil and start memantine (group 4) for 52 weeks. 
A 
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Figure 3. Comparison of the effect of discontinuing with continuing donepezil on risk of NHP in 
each category of randomisation minimisation strata and time period from randomisation. O-E 
refers to the difference between the Observed and Expected events within each strata and is the 
log-rank statistic. The comparison of the effect of memantine is not shown since there was no 
overall difference on event rate, stratified or un-stratified.  
*All excluding time from randomisation.  
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Figure 4: Graphs of fitted hazard (A) and cumulative probability of NHP (B) for flexible parametric 
survival model (dashed lines) with regions showing 95% confidence regions. Solid lines show fitted 
estimates and dashed line in B shows Kaplan-Meier (KM) non-parametric estimates. This was a 
post-hoc analysis to describe how the hazard (instantaneous risk) of NHP changes over time.  
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Table 1. Patient baseline characteristics by treatment arm.  
 
Discontinue donepezil Continue donepezil 
Total Add placebo 
memantine 
Add memantine 
Add placebo 
memantine 
Add memantine 
Total randomised 73 76 73 73 295 
Age in years at baseline / Mean (SD) 77.7 (8.0) 76.2 (8.9) 77.2 (7.5) 77.5 (9.0) 77.1 (8.4) 
Male / N (%) 26 (36%) 30 (39%) 22 (30%) 24 (33%) 102 (35%) 
Ethnicity 
N (%) 
White 71 (97%) 73 (96%) 69 (95%) 67 (92%) 280 (95%) 
Black 2 (3%) 2 (3%) 1 (1%) 4 (5%) 9 (3%) 
Other 0 1 (1%) 3 (4%) 2 (3%) 6 (2%) 
Donepezil duration 
prior to randomisation / 
N (%) 
3-<6Months 3 (4%) 4 (5%) 3 (4%) 4 (5%) 14 (5%) 
6- <12 Months 8 (11%) 4 (5%) 9 (12%) 3 (4%) 24 (8%) 
12+ Months 62 (85%) 68 (89%) 61 (84%) 66 (90%) 257 (87%) 
Male carer / N(%) 36 (49%) 31 (41%) 36 (49%) 34 (47%) 137 (46%) 
Carer lives with patient / N(%) 65 (89%) 58 (76%) 58 (79%) 53 (73%) 234 (79%) 
Relationship of 
carer/ N(%) 
Spouse or partner 56 (77%) 49 (64%) 41 (56%) 43 (59%) 189 (64%) 
Son or daughter 15 (21%) 18 (24%) 30 (41%) 28 (38%) 91 (31%) 
Other relative 0 7 (9%) 1 (1%) 1 (1%) 9 (3%) 
Friend or neighbour 0 2 (3%) 0 0 2 (1%) 
Paid Carer 2 (3%) 0 1 (1%) 1 (1%) 4 (1%) 
Mean (SD) sMMSE at baseline 9.1 (2.4) 9.2 (2.5) 9.0 (2.8) 9.1 (2.6) 9.1 (2.6) 
Mean (SD) BADLS at baseline 28.6 (8.9) 27.1 (9.0) 28.2 (9.0) 26.9 (9.8) 27.7 (9.2) 
Mean (SD) NPI at baseline 22.9 (17.0) 23.1 (16.2) 22.3 (16.7) 20.3 (14.4) 22.2 (16.1) 
Standardised Mini-Mental State Examination (sMMSE, range 0 to 30, higher scores indicate better cognitive function); Bristol Activities of Daily Living Scale 
(BADLS, range 0 to 60, higher scores indicate greater functional impairment); Neuropsychiatric Inventory (NPI, range 0 to 144, higher scores indicate 
increased behavioural and psychological symptoms) 
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Table 2. Summary of time to NHP and deaths by treatment arm. 
 
Discontinue donepezil Continue donepezil 
Add placebo 
memantine 
Add memantine 
Add placebo 
memantine 
Add memantine 
Total follow-up time at risk (person-years) 97.0 100.7 121.0 117.8 
Number of NHP events 42 (58%) 41 (54%) 36 (49%) 43 (59%) 
Observed NHP Rate per 10 person-years 
(95% CI) 
4.33 (3.20, 5.86) 4.07 (3.00, 5.53) 2.98 (2.15, 4.13) 3.65 (2.71, 4.92) 
Centiles of time to NHP 
in months (95% CI) 
25% 8.9 (2.6, 11.1) 9.0 (6.0, 12.0) 12.7 (9.5, 14.0) 12.8 (8.9, 15.2) 
50% (median) 16.7 (11.1, 26.2) 16.6 (12.0, 22.2) 21.9 (14.0, 40.9) 20.7 (15.2, 30.0) 
Probability of NHP by 
time after randomisation 
(95% CI) 
6 months 0.23 (0.15, 0.35) 0.15 (0.08, 0.26) 0.07 (0.03, 0.16) 0.06 (0.02, 0.15) 
12 months 0.37 (0.27, 0.50) 0.37 (0.26, 0.51) 0.21 (0.12, 0.33) 0.20 (0.12, 0.32) 
24 months 0.61 (0.48, 0.73) 0.66 (0.53, 0.79) 0.53 (0.40, 0.66) 0.53 (0.40, 0.67) 
36 months 0.71 (0.58, 0.83) 0.69 (0.56, 0.81) 0.62 (0.48, 0.75) 0.65 (0.53, 0.78) 
48 months 0.77 (0.64, 0.88) 0.76 (0.63, 0.87) 0.69 (0.56, 0.2) 0.86 (0.73, 0.95) 
Deaths before NHP  17 (23%)   12 (16%)   20 (27%)   17 (23%)  
Deaths reported after NHP    4 (5%)     7 (9%)    7 (10%)    8 (11%)  
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Table 3: Summary of time to NHP by donepezil group, and separately by memantine group. The analysis separated in 0-12 and 12-48 month periods was 
not a planned analysis, but is appropriate in the presence of non-proportional hazards.   
 
Continue 
donepezil 
Discontinue 
donepezil 
Difference 
between groups 
Add placebo 
memantine 
Add memantine 
Difference 
between groups 
Total randomised 146 149  149 146  
Overall 
Time at risk (years) 238.8 197.8  218.0 218.6  
Number of NHP events 79 83  78 84  
NHP Rate (per 10 years) 3.31 (2.65, 4.12) 4.20 (3.38, 5.20)  3.58 (2.87, 4.47) 3.84 (3.10, 4.76)  
Hazard ratio (95% CI) Reference 1.29 (0.95, 1.76)  Reference 1.08 (0.79, 1.47)  
Proportional hazards p = 0.010   p = 0.068   
0 – 12 
months 
Time at risk (years) 120.5 104.2  109.8 114.9  
Number of NHP events 26 46  37 35  
NHP Rate (per 10 years) 2.16 (1.47, 3.17) 4.42 (3.31, 5.89)  3.37 (2.44, 4.65) 3.05 (2.19, 4.24)  
Hazard ratio (95% CI) Reference 2.09 (1.29, 3.39)  Reference 0.92 (0.58, 1.45)  
12 – 48 
months 
Time at risk (years) 118.3 93.6  108.2 103.7  
Number of NHP events 53 37  41 49  
NHP Rate (per 10 years) 4.48 (3.42, 5.86) 3.95 (2.87, 5.46)  3.79 (2.79, 5.15) 4.73 (3.57, 6.25)  
Hazard ratio (95% CI) Reference 0.89 (0.58, 1.35)  Reference 1.23 (0.81, 1.87)  
Centiles of time to NHP 
in months (95% CI) 
25th 12.7 (10.4, 14.0) 8.9 (5.5, 10.1)    -3.8 (-7.0, -1.5)  10.1 (8.9, 12.6) 11.2 (8.9, 12.8)      1.1 (-2.7, 4.2)  
Median 21.9 (16.9, 29.1) 16.7 (12.7, 22.1)    -5.1 (-12.7, 2.6)  17.5 (14.0, 26.2) 19.6 (15.1, 24.1)      2.2 (-5.5, 9.3)  
Probability of NHP by 
time after 
randomisation, Kaplan-
Meier estimates 
(95% CI) 
6 months 0.06 (0.03, 0.12) 0.19 (0.13, 0.27)    0.13 (0.04, 0.21)  0.15 (0.10, 0.22) 0.10 (0.06, 0.17)  -0.05 (-0.12, 0.03)  
12 months 0.20 (0.14, 0.28) 0.37 (0.29, 0.46)    0.17 (0.06, 0.28)  0.29 (0.22, 0.38) 0.28 (0.21, 0.37)  -0.01 (-0.12, 0.10)  
24 months 0.53 (0.43, 0.62) 0.63 (0.54, 0.72)   0.11 (-0.02, 0.23)  0.56 (0.47, 0.66) 0.59 (0.50, 0.69)   0.03 (-0.10, 0.16)  
36 months 0.63 (0.54, 0.73) 0.69 (0.60, 0.78)   0.06 (-0.06, 0.21)  0.66 (0.57, 0.75) 0.67 (0.58, 0.76)   0.01 (-0.13, 0.15)  
48 months 0.77 (0.68, 0.85) 0.76 (0.67, 0.84)  -0.01 (-0.14, 0.13)  0.73 (0.63, 0.82) 0.81 (0.71, 0.88)   0.08 (-0.06, 0.20)  
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Panel: Research in context 
Evidence before this studyWe searched PubMed on 25/6/2015 for articles on studies of the effects of dementia drug treatments on nursing home placement 
using the following terms: “Alzheimer’s treatment” AND “Nursing home placement” and “Alzheimer’s treatment” AND “Care home placement” and 
“Cholinesterase inhibitor” AND “Placement”. We identified a single double-blind randomised controlled trial that demonstrated no effect of donepezil 
treatment on nursing home placement in mild to moderate Alzheimer’s disease and 11 open treatment or retrospective analyses that reported apparent 
delayed nursing home placement in patients taking cholinesterase inhibitor treatment. 
Added value of this study 
We showed that moderately-to-severely affected Alzheimer’s disease patients who continued donepezil treatment were at reduced risk of nursing home 
placement during the 12-months of a randomised double-blind controlled trial. Benefits were not maintained after 12 months at which point the patients’ 
treating physicians chose their treatment. Although our results should be considered exploratory as nursing home placement was a secondary outcome and 
analysis restricted to the first 12 months of follow-up was not pre-specified in the analysis plan, they indicate that along with cognitive and functional benefits, 
continuing cholinesterase inhibitor treatment is associated with advantages in maintaining independent home living. 
Implications of all the available evidence 
Because the symptomatic benefits associated with cholinesterase inhibitor treatment in Alzheimer’s disease are modest, it is difficult for physicians to 
evaluate whether their patients are deriving benefit from treatment and they may consider stopping treatment because of perceived lack of efficacy once 
patients have become moderately to severely affected. The evidence suggests that withdrawal of cholinesterase inhibitor treatment is associated with 
worse cognitive and functional outcomes and, from this study, earlier transfer to a nursing home. Decisions to continue or stop treatment in patients with 
moderate and severe Alzheimer’s disease should be made after consideration of these risks.  
 
